Biocartis Group N.V. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
35,620.00
9,118.00
39,797.00
49,777.00
41,960.00
48,153
Depreciation, Depletion & Amortization
3,557.00
4,437.00
5,021.00
4,848.00
5,096.00
4,273
Other Funds
2,061.00
26,997.00
297.00
290.00
1,700.00
5,663
Funds from Operations
30,002.00
31,678.00
35,073.00
44,639.00
38,564.00
38,217
Changes in Working Capital
11,077.00
4,146.00
11,822.00
8,594.00
2,841.00
3,797
Net Operating Cash Flow
41,079.00
35,824.00
23,251.00
53,233.00
41,405.00
42,014
Capital Expenditures
3,650.00
2,767.00
9,612.00
11,050.00
4,318.00
Sale of Fixed Assets & Businesses
-
7,514.00
92.00
1,629.00
-
Purchase/Sale of Investments
245.00
245.00
-
-
-
Net Investing Cash Flow
3,895.00
146.00
9,520.00
9,421.00
4,320.00
Issuance/Reduction of Debt, Net
4,088.00
3,379.00
3,258.00
10,406.00
1,413.00
Net Financing Cash Flow
33,770.00
17,865.00
125,943.00
41,804.00
75,256.00
Net Change in Cash
11,447.00
18,128.00
93,168.00
20,840.00
29,519.00
Free Cash Flow
44,217.00
37,751.00
32,492.00
62,356.00
44,562.00
Net Assets from Acquisitions
-
5,138.00
-
-
-
Change in Capital Stock
29,682.00
21,244.00
129,201.00
31,398.00
76,669.00
Exchange Rate Effect
243.00
23.00
4.00
10.00
12.00
Other Uses
-
-
-
-
2.00

About Biocartis Group

View Profile
Address
Generaal de Wittelaan 11 B3
Mechelen VL 2800
Belgium
Employees -
Website http://www.biocartis.com
Updated 07/08/2019
Biocartis Group NV is a commercial stage molecular diagnostics company, which engaegs in the provision of diagnostic solutions. It operates through MDx Idylla™ platform, an automated sample-to-result, real-time polymerase chain reaction system that offers molecular information from virtually any biological sample. The company was founded by Renaud Philippe, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.